Lundbeck has presented new six-month real-world data from the INFUSE study at the American Academy of Neurology 2026 meeting, showing that patients treated with Vyepti reported improvements in migraine-related cognitive symptoms such as brain fog, difficulty making decisions, reading comprehension problems, and trouble with complex tasks. The update adds a new layer to the commercial and clinical positioning of eptinezumab, which is already approved as a preventive migraine treatment for adults and competes in an increasingly mature calcitonin gene-related peptide inhibitor market.

Why Lundbeck is trying to expand the definition of migraine burden beyond headache days alone

The most important strategic signal in this data release is not merely that patients reported feeling better cognitively after treatment. It is that Lundbeck is making a deliberate case that migraine prevention should no longer be evaluated mainly through traditional measures such as monthly migraine days or monthly headache frequency. That shift matters because the CGRP class is no longer new, and differentiation is becoming harder. Once a therapeutic category matures, companies typically look for adjacent outcome domains that are clinically relevant, commercially persuasive, and meaningful to both physicians and patients. Cognitive symptoms are a logical candidate.

For years, migraine therapy development has leaned heavily on attack frequency, pain intensity, responder rates, and quality-of-life scales. Those remain central, but they do not fully capture how many patients describe the disease in daily life. The complaint of brain fog has long circulated in neurology clinics and patient communities, yet it has often remained under-quantified in formal evidence packages. Lundbeck is now trying to move that symptom from anecdotal complaint to measurable burden. That is a smart move because it reframes migraine as a broader neurological impairment rather than a narrower headache disorder.

This matters commercially because once physicians begin to think about cognitive dysfunction as a core part of migraine burden, treatment conversations may also change. Preventive therapies that can be associated with mental clarity, work functioning, and day-to-day productivity gain a more emotionally and practically resonant value proposition. However, the limitation is equally clear. Patient-reported improvement in cognition is compelling, but it does not automatically establish objective cognitive restoration, nor does it prove superiority against rival agents. Lundbeck is opening an important conversation, but not ending it.

Why real-world evidence can help Vyepti, but also leaves important questions unresolved

The INFUSE study format gives Lundbeck useful material for real-world positioning. In an established class, randomized controlled trial data tell only part of the story. Clinicians often want to know what happens in patients who are harder to treat, have already cycled through prior therapies, and resemble the people seen in specialist practice. INFUSE appears designed to answer that need. Its population includes adults with migraine who had already failed at least one prior preventive anti-CGRP treatment, which makes the findings more relevant to refractory or treatment-experienced segments.

That context helps the Vyepti narrative. If patients with prior anti-CGRP failure still report meaningful improvement after switching to eptinezumab, Lundbeck can argue that the drug remains relevant even later in the treatment pathway. In commercial terms, that is valuable because it supports persistence of use beyond early-line competition. In clinical terms, it suggests that not all CGRP-targeting agents will be treated as interchangeable by prescribers, especially when route of administration, onset profile, and patient experience differ.

Yet real-world evidence always comes with interpretive trade-offs. INFUSE is observational, not randomized. It relies heavily on participant-reported digital surveys. It did not collect safety data directly within the study framework, instead relying on established reporting channels. That does not invalidate the findings, but it means the dataset is more useful for hypothesis support and practice insight than for hard comparative conclusions. The absence of a control group is especially important. Cognitive symptoms in migraine can fluctuate with disease severity, sleep, stress, coexisting anxiety or depression, and broader lifestyle or treatment changes. Without tighter controls, it is difficult to isolate how much of the reported improvement is attributable specifically to the drug effect versus broader disease stabilization or reporting dynamics.

Why the emphasis on cognitive symptoms could strengthen physician conversations and payer arguments

One reason Lundbeck is spotlighting these results is that cognitive symptoms can translate better into functional language than many conventional migraine endpoints. A reduction in headache days is clinically important, but “fewer days with mental cloudiness” or “better ability to work and focus” can be more tangible when clinicians speak with patients and when market access teams build value dossiers. In the modern reimbursement environment, therapies increasingly need to show not just symptom change but also life impact.

That creates a strategic opportunity for Vyepti. The drug is given by intravenous infusion once every three months, which already distinguishes it from self-injected competitors and oral CGRP options. The infusion model can be framed as less convenient for some patients, but it can also be presented as structured care with predictable administration and complete dose delivery. If Lundbeck can pair that delivery model with a narrative of rapid and meaningful improvement in burdens that patients feel acutely, such as brain fog, the product story becomes more differentiated.

Still, reimbursement arguments based on cognitive symptom relief may face scrutiny unless the evidence matures further. Payers tend to prefer endpoints with established economic or utilization relevance. To move from an interesting clinical insight to a reimbursement lever, Lundbeck may eventually need stronger evidence tying cognitive improvements to work productivity, health resource use, treatment persistence, or reduced disability burden. The current data support the idea that cognition matters. They do not yet fully prove how that matters economically.

What this says about the next battleground in CGRP competition

The broader migraine market context is critical here. The CGRP field has evolved from breakthrough enthusiasm to competitive refinement. Multiple agents now target either the CGRP ligand or receptor, and physicians increasingly make choices based on practical differences, prior treatment history, tolerability, speed of effect, route of administration, and payer access. In that environment, incremental differentiation matters a great deal.

Lundbeck’s data suggest the company sees the next phase of competition not just in reducing migraine days but in owning underappreciated dimensions of disease burden. That is sensible because headache-day reduction alone is unlikely to produce durable narrative separation when many therapies already show efficacy. The companies that win share in a mature specialty market often do so by shaping how the disease itself is discussed. Lundbeck is trying to make migraine-related cognition one of those framing variables.

However, that strategy will only work if clinicians accept the premise that these symptoms are both common and treatment-responsive in a way that can be credibly measured. The company reported high baseline burden, with brain fog and other cognitive complaints described as moderately to extremely bothersome by a large proportion of participants. Those figures help establish prevalence. But for the strategy to really stick, the field may need broader validation through independent studies, cross-trial discussions, or even future endpoint development. Otherwise, the campaign risks being seen as interesting but sponsor-shaped.

Why the Day 7 signal is commercially useful, even if it needs cautious interpretation

Among the more commercially attractive features of the release is the claim that marked improvements were observed as early as Day 7 after treatment. Early benefit is always appealing in migraine, where patient frustration and discontinuation risk can be high. A drug that can be associated with quick symptom relief beyond headache frequency has a stronger story for neurologists managing patients with high unmet need.

That early timing also fits with Vyepti’s broader brand identity. Because it is delivered intravenously, Lundbeck has long leaned on the idea of rapid systemic availability compared with alternatives that require different pharmacokinetic pathways. The Day 7 cognitive improvement narrative complements that positioning nicely. It helps connect route of administration to perceived clinical payoff.

But caution is necessary. Early patient-reported changes can be influenced by expectation effects, treatment context, and the psychology of switching after prior failure. Without randomized comparison, the Day 7 finding is better viewed as a signal worth noting than a definitive proof point. Clinicians may find it encouraging, but scientific skeptics will want to see whether the effect holds consistently, how large it is, and whether it maps onto broader clinical outcomes.

Why safety and treatment experience still remain part of the adoption equation

Even when the new data focus on cognition, prescribing decisions for preventive migraine therapies still rest on a broader balance of efficacy, tolerability, convenience, and patient preference. Vyepti’s established label includes important safety considerations such as hypersensitivity reactions, postmarketing reports of hypertension, and Raynaud’s phenomenon. Those are not new issues in this announcement, but they remain relevant because any effort to widen use or deepen positioning must still pass through real-world treatment decision filters.

The infusion model is another double-edged factor. For some patients, quarterly administration under supervision may improve adherence and reduce the burden of frequent dosing. For others, infusion-center logistics may act as a barrier, especially if oral or self-administered alternatives are more accessible. That means Lundbeck’s cognitive symptom narrative may resonate most in specialist settings and among patients with substantial burden, prior treatment failure, or a desire for structured preventive care. It may be less persuasive in earlier-line or convenience-sensitive segments.

In other words, the new data help strengthen Vyepti’s identity, but they do not erase the practical trade-offs that shape uptake. The product’s commercial opportunity lies less in being everything to every migraine patient and more in becoming the preferred option for defined subgroups where burden is high and broader symptom control matters.

What clinicians and industry watchers are likely to monitor next after the INFUSE update

The most immediate question is whether Lundbeck can build on this signal with a more durable evidence package. That could include longer-term follow-up from INFUSE, subgroup analyses, correlations between cognitive improvement and other migraine measures, or external work exploring objective cognitive testing. Any of those would help move the discussion from intriguing patient-reported experience to more durable clinical framing.

Clinicians will also watch whether cognitive outcomes begin to appear more regularly in migraine congresses, guideline discussions, or comparative treatment conversations. If that happens, Lundbeck may deserve credit for pushing the field toward a more holistic understanding of disease burden. If not, the announcement may remain a useful but limited promotional differentiator within conference-cycle competition.

From an industry perspective, this release shows how specialty biopharma companies are adapting when they can no longer rely on novelty alone. Lundbeck is not simply saying Vyepti works. It is saying migraine treatment success should be judged more broadly, and that Vyepti belongs in that broader conversation. That is a sharper and more durable commercial argument than repeating legacy efficacy claims. The challenge now is proving that this expanded narrative can hold up clinically, economically, and competitively as the migraine market grows more crowded and more outcomes-driven.

  AAN 2026, CGRP inhibitors, eptinezumab, Lundbeck, migraine, neurology, preventive migraine treatment, real-world evidence, Vyepti